WebSep 22, 2024 · The phase 3 CheckMate-649 study demonstrated that first-line treatment with the combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal … WebAug 11, 2024 · CheckMate -649 is also evaluating the Opdivo plus Yervoy (ipilimumab) combination compared to chemotherapy in patients with gastric cancer, GEJ cancer or esophageal adenocarcinoma. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. About CheckMate -649
FDA approves nivolumab in combination with chemotherapy for metast…
WebApr 8, 2024 · Recently, not only chemotherapy, but also chemoradiotherapy, immunotherapy, and chemotherapy plus immunotherapy are performed for advanced esophageal cancer. 1,2,3 The Checkmate-648 trial revealed that both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus … WebJun 6, 2024 · Patients were randomized to nivolumab at 240 mg (n = 532) or placebo (n = 262) every 2 weeks for 16 weeks, followed by nivolumab at 480 mg or placebo every 4 weeks. the plane rd sharma
Update Supports Adjuvant Nivolumab as Standard Care in …
WebMar 31, 2024 · The landmark findings of the CheckMate-577 study, sponsored by Bristol Myers Squibb, represent a major research advancement in the treatment of esophageal (E) and gastroesophageal junction (GEJ) cancers utilizing the PD-1 inhibitor nivolumab as a novel, adjuvant treatment for operable stage II or stage III cancers following neoadjuvant ... WebAug 11, 2024 · CheckMate -577 is a Phase 3 randomized, multi-center, double-blind study evaluating Opdivo as an adjuvant therapy in patients with resected esophageal or GEJ … WebFeb 19, 2024 · This ASO perspective reviews the findings of a randomized placebo-controlled, clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma, reported recently by the Checkmate 577 investigators. The use of postoperative immunotherapy represents a significant paradigm shift for managing … the plane ride that never ends